Ask about this productRelated genes to: JAK3 antibody
- Gene:
- JAK3 NIH gene
- Name:
- Janus kinase 3
- Previous symbol:
- -
- Synonyms:
- L-JAK, JAKL, LJAK, JAK3_HUMAN, JAK-3
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-19
- Date modifiied:
- 2019-04-23
Related products to: JAK3 antibody
Related articles to: JAK3 antibody
- Pink lotus ( Gaertn.) contains bioactive flavonoids and alkaloids that exert anti-inflammatory and antioxidant activities, and inhibit TNF-α, IL-1β, IL-6 and NF-κB signaling pathways implicated in the pathogenesis of psoriasis. However, the effects of pink lotus flower oil (PLO) on psoriasis-like skin inflammation remain unexplored. Therefore, the present study aimed to evaluate the effects of PLO treatment on imiquimod (IMQ)-induced psoriasis-like skin inflammation in a mouse model. Briefly, BALB/c mice with IMQ-induced psoriasis were administered PLO (100 and 200 mg/kg), and the psoriasis area and severity index were measured. Histopathology, proinflammatory cytokine levels, antioxidant gene expression, oxidative stress and antioxidant marker levels, and immunoreactivity were also assessed. PLO treatment markedly reduced erythema, scaling and epidermal thickening, and suppressed keratinocyte proliferation, as evidenced by decreased proliferating cell nuclear antigen immunoreactivity, and downregulated mRNA levels of keratin-encoding genes 6 (), and . Moreover, PLO significantly downregulated the levels of proinflammatory cytokines, including TNF-α, IL-17A, IL-23 and , and reduced the infiltration of CD4 and mast cells. Mechanistically, PLO treatment decreased phosphorylated (p)-JAK2, p-JAK3 and p-STAT3 immunoreactivity by inhibiting JAK2/JAK3/STAT3 signaling. Oxidative stress was attenuated, as evidenced by reduced malondialdehyde levels, and increased nuclear factor erythroid 2-related factor 2, Cu/Zn-superoxide dismutase (), , catalase and glutathione peroxidase mRNA expression levels. PLO treatment also mitigated IMQ-induced splenomegaly, and suppressed expression in the spleen, and reduced expression in the axillary lymph nodes. In conclusion, PLO treatment ameliorated IMQ-induced psoriasis by enhancing antioxidant defenses, and by inhibiting JAK2 and JAK3/STAT3 signaling, supporting its potential as a therapeutic candidate for psoriasis. - Source: PubMed
Publication date: 2026/06/03
Jongsomchai KamonwanSridurongrit SomyothSukphopetch PassaneshRudtanatip TawutPromsrisuk TichanonPhuapittayalert LaorratJamsuwan SatapornChanmanee TeeraThummayot SarinthornThongrong SitthisakOnsa-Ard AmnartPudgerd Arnon - Severe combined immunodeficiency (SCID) is one of the most severe forms of primary immunodeficiency. gene is a critical determinant of SCID, as JAK3-STAT pathway regulates development, proliferation, activation, and differentiation of immune cells. This study aimed to identify the genetic cause of a family with a suspected SCID patient, and to perform carrier screening for two couples to assess the risk of conceiving offspring with birth defects. - Source: PubMed
Publication date: 2026/06/01
Peng YaoSang Yi-LinZhu WuZhang NingSun YiLin GeLu Guang-XiuTan Yue-QiuDu JuanWang Fu-YanHe Wen-Bin - CD4 T cells are central to adaptive immunity, with GATA binding protein 3 (Gata-3) acting as a key transcription factor for Th subset differentiation. This study aimed to characterize Gata-3 in flounder (Paralichthys olivaceus) and investigate its role in CD4 T cell differentiation via its zinc finger domains (ZnFs). Flounder Gata-3 contains two conserved C4-type ZnFs and showed peak expression in gills. Immunofluorescence assays suggested that Gata-3 located in gill leukocytes, co-localized with CD4-1/CD4-2 cells but not CD8 or IgM cells. Under in vitro Th2 differentiation, the proportion of CD4 cells increased from 15.77 ± 2.59% to 21.13 ± 1.92%. Concurrently, gata-3, jak3, stat6, il-10, and c-maf were significantly upregulated, while Th1-related genes (e.g., t-bet, ifn-γ) were significantly downregulated. Overexpression of Gata-3 in 293T cells significantly inhibited the promoters of t-bet and ifn-γ. Meanwhile, a recombinant plasmid of Gata-3 without the ZnFs was constructed and transfected into HINAE cells; this experiment that only Gata-3 was significantly upregulated, while no significant changes were observed in the expression of t-bet, ifn-γ, stat4, or il-12rβ. Furthermore, two mutants of Gata-3 lacking the C- or N-terminal ZnF were constructed, but only the mutant lacking the C-terminal ZnF exhibited no inhibition on t-bet and ifn-γ promoters. In conclusion, Gata-3 promotes Th2 differentiation while inhibiting the Th1 pathway in flounder by directly repressing T-bet and ifn-γ, a process critically mediated by its C-terminal ZnF. This study provides new insights into the evolutionary conservation of T cell immune regulation in teleosts. - Source: PubMed
Publication date: 2026/06/15
Duan ZhixiangHe ZiyangTang XiaoqianSheng XiuzhenChi HengXing JingZhan Wenbin - Ritlecitinib, a JAK3/TEC family kinase inhibitor, and baricitinib, a JAK1/2 inhibitor, are approved for treating severe alopecia areata (AA). - Source: PubMed
Publication date: 2026/06/11
Cha-Silva Ashley SZhang Kate HGraham Christopher NKurosky Samantha KTran HelenLaw Ernest HSong Eingun J - The immunodeficient mouse model offers a platform for evaluating therapeutic options in preclinical cancer research by enabling the growth of human xenografts. We previously developed BALB/c Rag2Jak3 (BRJ), an immunodeficient mouse model useful for cancer studies. However, susceptibility to xenograft acceptance can be increased through signal regulatory protein alpha (SIRPα)-CD47 signaling, also known as the "don't eat me" signal. In this study, we generated BALB/c human-SIRPα BAC transgenic mice and crossed them with BRJ mice. The resulting human SIRPα-transgenic BRJ (BRJ-S) mice showed a significantly higher engraftment rate of human B-cell lymphoma than BRJ mice. Furthermore, we demonstrated better human tumor engraftment in BRJ-S mice by reducing phagocytosis. In summary, hSIRPα-transgenic BRJ mice (BRJ-S) serve as a promising immunodeficient model with enhanced capacity for human lymphoma engraftment. BRJ-S provides an advantageous and permissive model for xenografting and for studying cancer in research and drug development. - Source: PubMed
Publication date: 2026/06/15
Panaampon JutatipOgawa TatsuyaShiota AkiraOkada Seiji